Last reviewed · How we verify
SAR407899A
At a glance
| Generic name | SAR407899A |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment (PHASE1)
- SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAR407899A CI brief — competitive landscape report
- SAR407899A updates RSS · CI watch RSS
- Sanofi portfolio CI